Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy

Breast Cancer

Volumn 21, Issue 3, 2014, Pages 284-291

  Aihara, Tomohiko ^a,j   Tanaka, Shiro ^b   Sagara, Yasuaki ^c   Iwata, Hiroji ^d   Hozumi, Yasuo ^e   Takei, Hiroyuki ^f   Yamaguchi, Hiroshi ^g   Ishitobi, Makoto ^h   Egawa, Chiyomi ⁱ  

^a Aihara Hospital   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c SAGARA HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f SAITAMA CANCER CENTER   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ KANSAI ROSAI HOSPITAL   (Japan)

^j NONE   (Japan)

more..

Author keywords

Adjuvant therapy; Aromatase inhibitor; Contralateral breast cancer; Ethnic difference; Tamoxifen

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; SEGMENTAL MASTECTOMY;

ANTIESTROGEN; TAMOXIFEN;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 84901334801     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0396-4     Document Type: Article

References (7)

1. Japanese Breast Cancer Society (2011) Clinical practice guideline of breast cancer. https://www.jbcsguideline.jp/. Accessed 26 October 2011.
2. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician-gls/pdf/ breast.pdf. Accessed 26 October 2011.
3. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000. (Pubitemid 29271743)
4. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21-9.
5. Kuo WH, Yen AM, Lee PH, Hou MF, Chen SC, Chen KM, et al. Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat. 2006;99:221-8. (Pubitemid 44268271)
6. Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. 2010;121:379-87.
7. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.